Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | SVP, Business Development | April 30, 2021 | May 04, 2021 |
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date April 30, 2021 · Filed May 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,146 |
Reported balance
After 2021-04-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-04-30 · Grant · Acquired 709 · Balance 45,146 F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively. |
| Common StockSEC Table I · non-derivative | Direct | 45,007 |
Reported balance
After 2021-05-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-05-01 · Tax withholding · Disposed 139 · Balance 45,007 |
| Common StockSEC Table I · non-derivative | Direct | 44,787 |
Reported balance
After 2021-05-03 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2021-05-03 · Tax withholding · Disposed 220 · Balance 44,787 F2: These shares include the following RSUs granted under the Company's equity plans: 326 RSUs which will vest on 4/27/2022; 1,133 RSUs which will vest in installments of 558 on 5/3/2022 and 575 on 5/3/2023; 1,269 RSUs which vest in installments of 418 on 5/5/2022, 419 on 5/5/2023 and 432 on 5/5/2024; and 709 RSUs which vest in installments of 233 on 4/30/2023, 234 on 4/30/2024 and 242 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3: These shares include 134 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. |
| Nqso (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $239.64 · Expires 2031-04-30 | Direct | 6,159 |
Reported balance
After 2021-04-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-04-30 · Grant · Acquired 6,159 · Balance 6,159 F4: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.
F2: These shares include the following RSUs granted under the Company's equity plans: 326 RSUs which will vest on 4/27/2022; 1,133 RSUs which will vest in installments of 558 on 5/3/2022 and 575 on 5/3/2023; 1,269 RSUs which vest in installments of 418 on 5/5/2022, 419 on 5/5/2023 and 432 on 5/5/2024; and 709 RSUs which vest in installments of 233 on 4/30/2023, 234 on 4/30/2024 and 242 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F3: These shares include 134 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.
F4: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.
Neumora Therapeutics, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2036-05-26 | Direct | 80,000 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 80,000 · Balance 80,000 F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 25, 2018 Filed Apr 26, 2018 23:17 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 217 | $171.94 | $37,310.98 |
DisclosureSEC source: 0001127602-18-015366 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,787 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 357 RSUs which vest in one installment on 1/30/2019; 1,023 RSUs with vest in 3 annual installments of 337, 338 and 348 on 5/3/2018, 5/3/2019 and 5/3/2020, respectively; and 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 112 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 23:48 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,519 | $176.08 | $267,465.52 |
DisclosureSEC source: 0001127602-18-012861 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,004 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 397 RSUs which vest on 4/25/2018; 357 RSUs which vest in one installment on 1/30/2019; 1,023 RSUs with vest in 3 annual installments of 337, 338 and 348 on 5/3/2018, 5/3/2019 and 5/3/2020, respectively; and 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 150 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 00:34 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 4,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011024 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,474 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 397 RSUs which vest on 4/25/2018; 357 RSUs which vest in one installment on 1/30/2019; 1,023 RSUs with vest in 3 annual installments of 337, 338 and 348 on 5/3/2018, 5/3/2019 and 5/3/2020, respectively; and 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 130 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| January 30, 2018 Filed Jan 31, 2018 01:38 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 153 | $198.00 | $30,294.00 |
DisclosureSEC source: 0001127602-18-003054 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,443 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 397 RSUs which vest on 4/25/2018; 357 RSUs which vest in one installment on 1/30/2018; 1,023 RSUs with vest in 3 annual installments of 337, 338 and 348 on 5/3/2018, 5/3/2019 and 5/3/2020, respectively; and 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 130 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| May 01, 2017 Filed May 4, 2017 00:58 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 8,714 | $0.00 Strike: $162.60 | $0.00 |
DisclosureSEC source: 0001127602-17-016759 · form4.xml · derivative · entry 2 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,714 Underlying: Common Stock · 8,714 shares Expires 2027-05-01 F4 · shares: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/1/2019, 5/1/2020 and 5/1/2021, respectively. Read SEC document |
| May 01, 2017 Filed May 4, 2017 00:58 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 984 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016759 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,533 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/1/2019, 5/1/2020 and 5/1/2021, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 397 RSUs which vest on 4/25/2018; 704 RSUs which vest in two installments of 347 and 357 on 1/30/2018 and 1/30/2019, respectively; 1,023 RSUs with vest in 3 annual installments of 337, 338 and 348 on 5/3/2018, 5/3/2019 and 5/3/2020, respectively; and 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.mmon stock on a one-to-one basis. F3 · balance_after: These shares include 92 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| April 26, 2017 Filed Apr 27, 2017 00:10 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 2,620 | $164.70 | $431,514.00 |
DisclosureSEC source: 0001127602-17-015593 · form4.xml · nonDerivative · entry 3 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,549 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 397 RSUs which vest on 4/25/2018; 704 RSUs which vest in two installments of 347 and 357 on 1/30/2018 and 1/30/2019, respectively; and 1,023 RSUs with vest in 3 annual installments of 337, 338 and 348 on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 92 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| April 26, 2017 Filed Apr 27, 2017 00:10 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 163 | $164.70 | $26,846.10 |
DisclosureSEC source: 0001127602-17-015593 · form4.xml · nonDerivative · entry 2 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,169 Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 00:10 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 215 | $163.14 | $35,075.10 |
DisclosureSEC source: 0001127602-17-015593 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,332 Read SEC document |
| March 24, 2017 Filed Mar 28, 2017 23:01 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 2,528 | $166.04 | $419,749.12 |
DisclosureSEC source: 0001127602-17-013098 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,547 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 286 RSUs which vest on 4/26/2017; 4,613 RSUs which vest on 4/26/2017; 782 RSUs which vest in two installments of 385 and 397 on 4/25/2017 and 4/25/2018, respectively; 704 RSUs which vest in two installments of 347 and 357 on 1/30/2018 and 1/30/2019, respectively; and 1,023 RSUs with vest in 3 annual installments of 337, 338 and 348 on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 546 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 22:17 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 5,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-011104 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,989 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 286 RSUs which vest on 4/26/2017; 4,613 RSUs which vest on 4/26/2017; 782 RSUs which vest in two installments of 385 and 397 on 4/25/2017 and 4/25/2018, respectively; 704 RSUs which vest in two installments of 347 and 357 on 1/30/2018 and 1/30/2019, respectively; and 1,023 RSUs with vest in 3 annual installments of 337, 338 and 348 on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 496 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 00:27 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 160 | $157.16 | $25,145.60 |
DisclosureSEC source: 0001127602-17-003216 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,354 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 286 RSUs which vest on 4/26/2017; 4,613 RSUs which vest on 4/26/2017; 782 RSUs which vest in two installments of 385 and 397 on 4/25/2017 and 4/25/2018, respectively; 704 RSUs which vest in two installments of 347 and 357 on 1/30/2018 and 1/30/2019, respectively; and 1,023 RSUs with vest in 3 annual installments of 337, 338 and 348 on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 496 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| May 03, 2016 Filed May 6, 2016 00:38 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 8,711 | $0.00 Strike: $156.35 | $0.00 |
DisclosureSEC source: 0001127602-16-051295 · form4.xml · derivative · entry 2 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,711 Underlying: Common Stock · 8,711 shares Expires 2026-05-03 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. Read SEC document |
| May 03, 2016 Filed May 6, 2016 00:38 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-051295 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,359 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 286 RSUs which vest on 4/26/2017; 4,613 RSUs which vest on 4/26/2017; 782 RSUs which vest in two installments of 385 and 397 on 4/25/2017 and 4/25/2018, respectively; 1,050 RSUs which vest in three annual installments of 346, 347 and 357 on 1/30/2017, 1/30/2018 and 1/30/2019, respectively; and 1,023 RSUs which vest in three installments of 337, 338 and 348 on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 357 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| April 27, 2016 Filed Apr 29, 2016 00:48 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 289 | $162.85 | $47,063.65 |
DisclosureSEC source: 0001127602-16-050230 · form4.xml · nonDerivative · entry 2 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,336 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 286 RSUs which vest on 4/26/2017; 4,613 RSUs which vest on 4/26/2017; 782 RSUs which vest in two installments of 385 and 397 on 4/25/2017 and 4/25/2018, respectively; and 1,050 RSUs which vest in three annual installments of 346, 347 and 357 on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 357 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| April 26, 2016 Filed Apr 29, 2016 00:48 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 154 | $163.46 | $25,172.84 |
DisclosureSEC source: 0001127602-16-050230 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,635 Read SEC document |
| April 25, 2016 Filed Apr 26, 2016 23:42 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 210 | $163.19 | $34,269.90 |
DisclosureSEC source: 0001127602-16-049947 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,789 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 510 RSUs which vest on 4/27/2016; 563 RSUs which vest in one installment of 277 on 4/26/2016 and one installment of 286 on 4/26/2017; 4,613 RSUs which vest on 4/26/2017; 782 RSUs which vest in two installments of 385 and 397 on 4/25/2017 and 4/25/2018, respectively; and 1,050 RSUs which vest in three annual installments of 346, 347 and 357 on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 413 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| March 25, 2016 Filed Mar 29, 2016 21:26 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 2,307 | $149.24 | $344,296.68 |
DisclosureSEC source: 0001127602-16-047740 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,999 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 510 RSUs which vest on 4/27/2016; 563 RSUs which vest in one installment of 277 on 4/26/2016 and one installment of 286 on 4/26/2017; 4,613 RSUs which vest on 4/26/2017; 1,166 RSUs which vest in annual installments of 384, 385 and 397 on 4/25/2016, 4/25/2017 and 4/25/2018, respectively; and 1,050 RSUs which vest in three annual installments of 346, 347 and 357 on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 428 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| March 02, 2016 Filed Mar 4, 2016 23:22 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 5,305 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-045132 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,212 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 510 RSUs which vest on 4/27/2016; 563 RSUs which vest in one installment of 277 on 4/26/2016 and one installment of 286 on 4/26/2017; 4,613 RSUs which vest on 4/26/2017; 1,166 RSUs which vest in annual installments of 384, 385 and 397 on 4/25/2016, 4/25/2017 and 4/25/2018, respectively; and 1,050 RSUs which vest in three annual installments of 346, 347 and 357 on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 371 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| April 27, 2015 Filed Apr 29, 2015 00:10 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 274 | $167.91 | $46,007.34 |
DisclosureSEC source: 0001127602-15-015482 · form4.xml · nonDerivative · entry 4 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,784 F1 · balance_after: These shares include 248 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| April 26, 2015 Filed Apr 29, 2015 00:10 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 2,497 | $167.91 | $419,271.27 |
DisclosureSEC source: 0001127602-15-015482 · form4.xml · nonDerivative · entry 3 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,058 Read SEC document |
| April 26, 2015 Filed Apr 29, 2015 00:10 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 151 | $167.91 | $25,354.41 |
DisclosureSEC source: 0001127602-15-015482 · form4.xml · nonDerivative · entry 2 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,555 Read SEC document |
| April 25, 2015 Filed Apr 29, 2015 00:10 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 330 | $167.91 | $55,410.30 |
DisclosureSEC source: 0001127602-15-015482 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,706 Read SEC document |
| March 27, 2015 Filed Mar 31, 2015 22:59 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 4,402 | $160.55 | $706,741.10 |
DisclosureSEC source: 0001127602-15-012985 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,036 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 632 RSUs which fully vest on 4/25/2015; 1,005 RSUs which vest in two annual installments of 495 on 4/27/2015 and 510 on 4/27/2016; 840 RSUs which vest in two equal installments of 277 each on 4/26/2015 and 4/26/2016 and one installment of 286 on 4/26/2017; 9,226 RSUs which vest in two equal installments of 4,613 each on 4/26/2015 and 4/26/2017; 1,166 RSUs which vest in annual installments of 384, 385 and 397 on 4/25/2016, 4/25/2017 and 4/25/2018, respectively; and 1,050 RSUs which vest in three annual installments of 346, 347 and 357 on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 455 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| March 04, 2015 Filed Mar 7, 2015 02:10 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 9,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-010548 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,321 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 632 RSUs which fully vest on 4/25/2015; 1,005 RSUs which vest in two annual installments of 495 on 4/27/2015 and 510 on 4/27/2016; 840 RSUs which vest in two equal installments of 277 each on 4/26/2015 and 4/26/2016 and one installment of 286 on 4/26/2017; 9,226 RSUs which vest in two equal installments of 4,613 each on 4/26/2015 and 4/26/2017; 1,166 RSUs which vest in annual installments of 384, 385 and 397 on 4/25/2016, 4/25/2017 and 4/25/2018, respectively; and 1,050 RSUs which vest in three annual installments of 346, 347 and 357 on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 386 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| January 30, 2015 Filed Feb 4, 2015 00:12 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-004145 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,862 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 632 RSUs which fully vest on 4/25/2015; 1,005 RSUs which vest in two annual installments of 495 on 4/27/2015 and 510 on 4/27/2016; 840 RSUs which vest in two equal installments of 277 each on 4/26/2015 and 4/26/2016 and one installment of 286 on 4/26/2017; 9,226 RSUs which vest in two equal installments of 4,613 each on 4/26/2015 and 4/26/2017; 1,166 RSUs which vest in annual installments of 384, 385 and 397 on 4/25/2016, 4/25/2017 and 4/25/2018, respectively; and 1,050 RSUs which vest in three annual installments of 346, 347 and 357 on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 386 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| August 03, 2014 Filed Aug 4, 2014 23:26 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-024687 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,711 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 632 RSUs which fully vest on 4/25/2015; 1,005 RSUs which vest in 2 annual installments of 495 on 4/27/2015 and 510 on 4/27/2016; 840 RSUs which vest in 2 equal installments of 277 each on 4/26/2015 and 4/26/2016 and one installment of 286 on 4/26/2017; 9,226 RSUs which vest in 2 equal installments of 4,163 each on 4/26/2015 and 4/26/2017; and 1,166 RSUs which vest in annual installments of 384, 385 and 397 on 4/25/2016, 4/25/2017 and 4/25/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 285 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 21:59 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 10 | $111.41 | $1,114.10 |
DisclosureSEC source: 0001127602-14-015512 · form4.xml · nonDerivative · entry 4 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,604 F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 3,750 RSUs which fully vest on 8/3/2014; 632 RSUs which fully vest on 4/25/2015; 1,005 RSUs which vest in 2 annual installments of 495 on 4/27/2015 and 510 on 4/27/2016; 840 RSUs which vest in 2 equal installments of 277 each on 4/26/2015 and 4/26/2016 and one installment of 286 on 4/26/2017; and 9,226 RSUs which vest in 2 equal installments of 4,163 each on 4/26/2015 and 4/26/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 221 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 21:59 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 259 | $111.41 | $28,855.19 |
DisclosureSEC source: 0001127602-14-015512 · form4.xml · nonDerivative · entry 3 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,614 Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:59 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-015512 · form4.xml · nonDerivative · entry 2 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,873 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 4/25/2016, 4/25/2017 and 4/25/2018. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:59 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 320 | $113.72 | $36,390.40 |
DisclosureSEC source: 0001127602-14-015512 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,707 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.